Lee D.M., and Weinblatt M.E. Rheumatoid arthritis. Lancet 358 (2001) 903-911
Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
Egeland T., and Munthe E. The role of the laboratory in rheumatology. Rheumatoid factors. Clin Rheum Dis 9 (1983) 135-160
Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43 (2000) 1831-1835
Goldblatt F., and Isenberg D.A. New therapies for rheumatoid arthritis. Clin Exp Immunol 140 (2005) 195-204
van Boekel M.A., Vossenaar E.R., van den Hoogen F.H., and van Venrooij W.J. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4 (2002) 87-93
Serre G., Vincent C., Fournie B., Lapeyre F., Soleilhavoup J.P., and Fournie A. Anti-stratum corneum antibody in the rat esophagus, anti-epidermal keratin and anti-epidermis autoantibodies in rheumatoid polyarthritis and other rheumatic diseases. Diagnostic value and basic aspects. Rev Rhum Mal Osteo-Artic 53 (1986) 607-614
Union A., Meheus L., Humbel R.L., et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 46 (2002) 1185-1195
Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., and van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101 (1998) 273-281
Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43 (2000) 155-163
Visser H., le Cessie S., Vos K., Breedveld F.C., and Hazes J.M. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46 (2002) 357-365
Suzuki K., Sawada T., Murakami A., et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32 (2003) 197-204
van Venrooij W.J., Hazes J.M., and Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60 (2002) 383-388
Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 21 (2002) 34-36
Bizzaro N., Mazzanti G., Tonutti E., Villalta D., and Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47 (2001) 1089-1093
Jansen A.L., van der Horst-Bruinsma I., van Schaardenburg D., van de Stadt R.J., de Koning M.H., and Dijkmans B.A. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29 (2002) 2074-2076
Bas S., Genevay S., Meyer O., and Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42 (2003) 677-680
Dubucquoi S., Solau-Gervais E., Lefranc D., et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63 (2004) 415-419
van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50 (2004) 709-715
Vittecoq O., Incaurgarat B., Jouen-Beades F., et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135 (2004) 173-180
Vallbracht I., Rieber J., Oppermann M., Forger F., Siebert U., and Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63 (2004) 1079-1084
van Jaarsveld C.H., ter Borg E.J., Jacobs J.W., et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17 (1999) 689-697
Goldbach-Mansky R., Lee J., McCoy A., et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2 (2000) 236-243
Lee D.M., and Schur P.H. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62 (2003) 870-874
Vincent C., Serre G., Fournie B., Fournie A., and Soleilhavoup J.P. Natural IgG to epidermal cytokeratins vs IgG to the stratum corneum of the rat oesophagus epithelium, so-called 'antikeratin antibodies', in rheumatoid arthritis and other rheumatic diseases. J Autoimmun 4 (1991) 493-505
Meyer O., Fabregas D., Cyna L., and Ryckewaert A. Anti-keratin antibodies. A marker of progressive rheumatoid arthritis. Rev Rhum Mal Osteo-Artic 53 (1986) 601-605
Zeng X., Ai M., Tian X., et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30 (2003) 1451-1455
